ArticleCureus2025
A Survey on the Awareness of Epilepsy Treatments in Community Pharmacies.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor effective epileptic seizure management, pharmacies need to provide physicians with information regarding drug-drug interactions, drugs that lower seizure thresholds, and switching to generic drugs. The aim of the study was to clarify the actual situation of information provision from pharmacies to physicians and investigate awareness of epilepsy treatment in community pharmacies.
methodsA survey targeting all pharmacies (1,512 pharmacies) belonging to the Hiroshima Prefectural Pharmacists Association was conducted from October 7, 2023, to November 30, 2023. The survey investigated the dispensing status of antiseizure medication (ASM) prescriptions and the feedback rate to physicians regarding drug interactions, seizure-threshold-lowering drugs, and switching to generics. We also evaluated the relationship between the frequency of patient care, the status of information provision, and switching to generic medications.
resultsOf the 197 pharmacies that responded, 181 (92%) had experience with ASM prescriptions. Ninety-five pharmacies (48%) provided feedback to physicians on interactions with newly prescribed ASMs. Precautions for interactions between new drugs and ongoing ASMs were addressed in 98 pharmacies (50%). Additionally, 86 pharmacies (44%) provided feedback on new drugs that lower the seizure threshold. Generic switching occurred in 143 pharmacies (73%). Information for physicians was provided via medicine notebooks in 160 cases (81%), while preconfirmation was conducted in only 10 cases (5%). Pharmacies providing patient care at least once a week were more likely to provide information about newly prescribed concomitant medications (p = 0.04), but no significant difference was found in other cases. They were also more likely to switch to generic drugs (p < 0.01), but there was no difference in providing information to physicians before confirmation.
conclusionsFeedback rates to physicians regarding interactions requiring precautions and threshold-lowering drugs were 50% or less, and prior confirmation when switching to generic drugs was rare. Further promotion of hospital-pharmacy information sharing is needed for more appropriate seizure management in patients with epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.